Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00720018 | Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers | PHASE1 | COMPLETED | 4 | — | — | Jun 1, 2008 | Jul 1, 2008 | Feb 3, 2016 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Period 1 | EXPERIMENTAL | NP101 Patch |
| Period 2 | EXPERIMENTAL | NP101 Patch |
| Period 3 | EXPERIMENTAL | NP101 Patch |
| Period 4 | EXPERIMENTAL | NP101 Patch |
| Period 5 | EXPERIMENTAL | NP101 Patch |
| Name | Type | Description |
|---|---|---|
| NP101 Sumatriptan Iontophoretic Transdermal Patch | DRUG | NP101 transdermal patch delivering sumatriptan for 4 hours. |
Inclusion Criteria: * Healthy Caucasian men or women aged 18 to 45. * Subjects have BMI of 18 to 30 kg/m2 inclusive. * Subject judged to be in good health, based upon the results of a medical history, physical examination, vital signs, ECG and laboratory profile. Subjects will not have any clinical...